• Home
  • Store
    • Newsletter Subscriptions
    • Multimedia Subscriptions
    • Books
    • eBooks
    • ABPN SA Courses
  • CME Center
  • Multimedia
    • Podcast
    • Webinars
    • Blog
  • Newsletters
    • General Psychiatry
    • Child Psychiatry
    • Addiction Treatment
    • Hospital Psychiatry
    • Geriatric Psychiatry
    • Psychotherapy and Social Work
  • Log In
  • Register
  • Welcome
  • Sign Out
  • Subscribe
Home » Estrogen Modulator Raloxifene Not Helpful for Schizophrenic Women

Estrogen Modulator Raloxifene Not Helpful for Schizophrenic Women

January 1, 2018
Robert T. Rubin, MD
From The Carlat Psychiatry Report
Issue Links: Learning Objectives | Editorial Information | PDF of Issue
Robert T. Rubin, MD Dr. Rubin has disclosed that he has no relevant financial or other interests in any commercial companies pertaining to this educational activity.
Review of: Weiser M et al, J Clin Psychiatry 2017;78:e758–e765

Since estrogen can affect neurotransmitter functioning, there has been some interest in using estrogen modulators to treat psychiatric conditions, including schizophrenia. Raloxifene is a selective estrogen receptor modulator (SERM) with some preliminary evidence for effectiveness in women with schizophrenia.

In this double-blind, multi-center study, 200 postmenopausal schizophrenic/schizoaffective women were treated for 16 weeks with either raloxifene or placebo augmentation of their antipsychotic drug treatment regimen. The study was conducted at 38 sites in Romania and Moldova, suggesting an average of 5 patients per site. The results were unequivocally negative. Indeed, subjects in the raloxifene treatment group fared significantly worse on the Positive and Negative Syndrome Scale (PANSS) than did the placebo group, an unexpected outcome the authors attribute to chance. There were no significant differences between groups in Clinical Global Impression—Severity or Composite Brief Assessment of Cognition in Schizophrenia scores.

TCPR’s Take
As the authors indicate, their data “does not support the use of raloxifene in severely decompensated schizophrenia patients.” These results are clear, but they may not be definitive. Given the many research sites, the potential for inter-site variability (in diagnosis, conduct of the study, assessments, etc) was quite large. In addition, the postmenopausal schizophrenic women had been ill for an average of over 20 years and had an average of about 20 hospitalizations, suggesting they were refractory to conventional treatments. There is a need for additional studies, with more subjects per site, less-ill women, and perhaps different SERMs.
General Psychiatry
KEYWORDS antipsychotics research-update women's_issues_in_psychiatry
    Robert T. Rubin, MD

    More from this author
    www.thecarlatreport.com
    Issue Date: January 1, 2018
    SUBSCRIBE NOW
    Table Of Contents
    CME Post-Test - Bipolar Disorder, TCPR, January 2018
    Note From the Editor-in-Chief
    Understanding the Bipolar Spectrum: Tips on Diagnosis
    Estrogen Modulator Raloxifene Not Helpful for Schizophrenic Women
    The Bipolar Spectrum: Practical Tips for Diagnosis and Treatment
    DOWNLOAD NOW
    Featured Book
    • PB4e_Cover2.png

      Psychiatry Practice Boosters, Fourth Edition (2023)

      Teaches you the key points of 63 of the most clinically relevant studies in psychiatry.
      READ MORE
    Featured Video
    • therapist_canstockphoto9201097.jpg
      General Psychiatry

      Using SAMe In Clinical Practice with Garrett Rossi, MD

      Read More
    Featured Podcast
    • canstockphoto6759394.jpg
      General Psychiatry

      Throwback Thursday: Brief Therapy for ADHD

      You started a stimulant medication for a young woman with ADHD. When she returns her symptoms are 70% better, but what can we do about the rest? Today a conversation with...

      Listen now
    Recommended
    • Approaches to Autism Intervention

      January 31, 2022
      canstockphoto2240982_child-bubbles_thumb.jpg
    • Currently Available Cannabis Products

      September 1, 2022
    • Interpreting Assessment Discrepancies from Multiple Sources

      October 17, 2022
      ChildAssessment.png
    • Approaches to Autism Intervention

      January 31, 2022
      canstockphoto2240982_child-bubbles_thumb.jpg
    • Currently Available Cannabis Products

      September 1, 2022
    • Interpreting Assessment Discrepancies from Multiple Sources

      October 17, 2022
      ChildAssessment.png
    • Approaches to Autism Intervention

      January 31, 2022
      canstockphoto2240982_child-bubbles_thumb.jpg
    • Currently Available Cannabis Products

      September 1, 2022
    • Interpreting Assessment Discrepancies from Multiple Sources

      October 17, 2022
      ChildAssessment.png

    About

    • About Us
    • CME Center
    • FAQ
    • Contact Us

    Shop Online

    • Newsletters
    • Multimedia Subscriptions
    • Books
    • eBooks
    • ABPN Self-Assessment Courses

    Newsletters

    • The Carlat Psychiatry Report
    • The Carlat Child Psychiatry Report
    • The Carlat Addiction Treatment Report
    • The Carlat Hospital Psychiatry Report
    • The Carlat Geriatric Psychiatry Report
    • The Carlat Psychotherapy Report

    Contact

    info@thecarlatreport.com

    866-348-9279

    PO Box 626, Newburyport MA 01950

    Follow Us

    Please see our Terms and Conditions, Privacy Policy, Subscription Agreement, Use of Cookies, and Hardware/Software Requirements to view our website.

    © 2023 Carlat Publishing, LLC and Affiliates, All Rights Reserved.